South San Francisco, CA — December 1, 2025 — Leads & Copy — Vistagen, a biopharmaceutical company, has appointed Nick Tressler as Chief Financial Officer, effective today.
Shawn Singh, President and CEO of Vistagen, expressed enthusiasm for Tressler’s appointment, citing his financial acumen, strategic thinking, and extensive experience in the biopharmaceutical industry as crucial for the company’s next phase. Singh anticipates Tressler’s contributions to the leadership team and his overall positive impact as the company pursues its vision.
Tressler brings over 20 years of financial leadership in the life sciences. He most recently served as CFO of DYNEX Technologies. Prior to that, Tressler held CFO positions at American Gene Technologies, International, and Senseonics Holdings, Inc. (Nasdaq: SENS). He also held senior finance roles at Sucampo Pharmaceuticals, acquired by Mallinckrodt in 2018, and MedImmune LLC, acquired by AstraZeneca PLC (Nasdaq: AZN) in 2007.
Tressler stated he was honored to join Vistagen. He cited the company’s pivotal moment, with clinical milestones on the horizon, a deep pipeline, and a team dedicated to innovative therapies for patients. He added he looks forward to collaborating with the team to advance strategic priorities with financial strategies aimed at long-term shareholder value creation.
Vistagen’s Board of Directors’ Compensation Committee granted Tressler an incentive option to purchase 150,000 shares of Vistagen’s common stock. This was an inducement for Tressler to join Vistagen, in accordance with Nasdaq Listing Rule 5635(c)(4). The option’s exercise price will equal the closing price of Vistagen’s common stock on December 1, 2025. Twenty-five percent of the shares will vest on the first anniversary of the grant, with the remainder vesting monthly over the following 36 months.
Vistagen, headquartered in South San Francisco, CA, is a clinical-stage biopharmaceutical company focused on developing and commercializing intranasal product candidates known as pherines. These pherines selectively bind to peripheral receptors on nasal chemosensory neurons, triggering neurocircuits that regulate brain areas related to behavior and autonomic nervous system activity. This approach aims to provide therapeutic benefits without systemic absorption or brain uptake, potentially offering a safer alternative to traditional pharmacological treatments.
Vistagen focuses on creating transformative treatment options for underserved individuals with conditions like social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
Contact:
Mark McPartland
Senior Vice President and Chief Corporate Development Officer
Phone: 650-577-3617
Email: markmcp@vistagen.com
Source: Vistagen
